181
CONJ • 18/4/08 RCSIO • 18/4/08
treatment, suggesting the impairment could have been due, at least
in part, to the anxiety and stress of having been diagnosed with
cancer. This would imply the need for baseline assessment of
cognitive status prior to treatment. Schagen and van Dam (1998)
report 32% of breast cancer patients who received high-dose
chemotherapy were cognitively impaired in comparison to 16%
who received standard dose chemotherapy and Schagen et al.
(1999) concluded a chemotherapy group of breast cancer patients
exhibited heightened levels of impairment in the areas of
concentration, memory, attention, and verbal function in contrast to
a surgically treated group. An extensive review of studies (n=57
with 3,424 patients) of cognitive functioning after chemotherapy in
adult patients concluded there were similar effects for those treated
with chemotherapy as those treated with cranial irradiation. In the
28 trials reporting quantitative data on patients with cognitive
deficits after treatment, 44.1% (range 18%–75%) of 451 patients in
the chemotherapy group, 44% (range 29%–83%) of 320 patients in
the radiotherapy group, and 64.5% (range 30%–100%) of 229
patients in the combined irradiation and chemotherapy group had
deficits.
Clearly, the evidence is growing that cognitive change occurs for
cancer patients. Unfortunately, the available literature’s sole focus has
been on quantifying the phenomenon of cognitive impairment or
“chemobrain”. Study of the patient perspectives and experiences in
living with cognitive impairment after treatment has not been
undertaken. Health care professionals know the incidence and nature
of side effects, but they also need to understand the impact the side
effect has from the patient’s perspective and how to assist patients in
coping with subsequent changes.
Purpose
The purpose of this exploratory study was to understand and
document cancer patients’ experiences with changes in cognitive
functioning following cancer treatment. Gaining insight into
patients’ perspectives about the impact of these cognitive changes
on daily living and the strategies they have found to be useful in
coping with the respective changes was seen as valuable in
guiding the development of future informational and support
interventions for patients who are at risk for, or have experienced
cognitive changes (i.e., “chemo brain”), and for their family
members.
Methods
This exploratory qualitative study used in-depth interviews with
cancer patients receiving treatment for their disease. Following
ethical review by the Hospital Research Ethics Committee a
purposive sample was accrued from a comprehensive cancer
program. Nurses caring for the patients told them that the study was
being conducted if they met the following criteria: 18 years of age
or older, English-speaking, no history of mental illness within the
last six months, no use of medication (antidepressants, narcotics) in
the last six months, started chemotherapy treatment a minimum of
six months ago, received a definitive diagnosis of breast,
gastrointestinal, genitourinary, gynecological, hematological, skin
or lung cancer, and reported experiencing mental “fogginess”,
difficulty remembering or concentrating since start of
chemotherapy. If the patient was interested in hearing about the
study, the nurse contacted the research assistant (RA) who informed
the patient about the details of the study purpose and participation.
Those who wanted to participate signed a written consent form.
Participation involved one interview regarding the person’s
experiences with cognitive changes that had occurred since
receiving treatment, the impact of these changes, and what
strategies the person has used to deal with the changes. The
interviews took between 30 and 60 minutes, depending on how
much detail the patient wished to share.
The open-ended questions used in the interview were designed to
encourage exploration of the patient’s own perspectives about the
cognitive changes they were experiencing. Once several
demographic questions had been asked (i.e., age, work status,
marital status, educational status, cancer type, date of diagnosis)
participants were asked in an open-ended manner to describe the
events surrounding the diagnosis and treatment of their cancer. This
was followed by queries about what cognitive changes they had
noticed, what impact the changes had, what they had done to deal
with the changes, what they found helpful, and what the cancer
centre might do to assist patients with this type of experience.
Probes were only used to encourage elaboration (i.e., tell me more
about) or to seek clarification (e.g., did that happen before or after
the treatment?).
The words “cognitive changes” were used in talking with
patients about this work during our interviews. However, our
experience with the pilot interviews revealed that we needed to add
examples of cognitive changes for clarification purposes (i.e., we
told patients that cognitive changes include things such as not
remembering names and numbers). The word cognitive did not
have meaning for individuals in our pilot work. During the initial
testing of the interview guide, we also identified the need to ask
each patient about each type of cognitive change. Patients struggled
in describing the full range of changes they had experienced.
Therefore, in the interview, we first asked an open-ended question
(i.e., what type of cognitive changes have you experienced?) and
let each person mention the ones he or she wanted to mention and
talk about those in detail. We then followed up with a specific
question about any cognitive changes that had not been mentioned
by the patients (e.g., have you noticed changes in doing
calculations?). Our “checklist” of cognitive changes was created
after reading the literature on potential for cognitive change
following chemotherapy. In the end, the interview became
somewhat more structured than we had originally intended. All of
the interviews were conducted by the RA and audiotaped for future
transcription. At the end of the interview, general information about
cognitive changes was provided and the offer of support or referral
extended to each patient.
All interview tapes were transcribed verbatim and identifying
features removed. A content analysis was performed (Speziale &
Carpenter, 1999) using all interviews, including our pilot interviews.
All team members independently read each transcript in its entirety
and made marginal notes about the content. The team members then
discussed their impressions of the interview content and, working
collaboratively, designed an overall categorization scheme (set of
categories) for the subsequent analysis. All interviews were then
coded on the basis of this agreed-upon scheme by one team member
(MF). The content within each category was then reviewed in-depth
and summarized, and the key ideas were identified. These key ideas
are reported below as they concern patients’ experiences with
cognitive changes following cancer treatment.
Findings
Sample
A total of 32 cancer patients participated in this study. The seven
men and 25 women ranged in age from 20 to 72 years (average 57.2).
Twenty-four were married or living with a partner and eight were
continuing to work during their treatment. A cross-section of cancer
types was included (See Table One). Twelve were living with
metastatic disease. Allocation of numbers by two different research
assistants resulted in numbers assigned for 33 and 35.
Context of the interviews
The participants in this study described the shock and dismay they
felt when their cancer was diagnosed and the initial treatment
decisions were made. They were keenly aware of the disruptions
doi:10.5737/1181912x184180185